Biomedical HIV Prevention Strategies
Source: 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention

Expert Analysis

In this report on the 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sharon L. Hillier, PhD, Julio Montaner, MD, FRCPC, FCCP, and Thomas Quinn, MD, MSc, provide insight on several reports of prevention strategies and review the challenges and successes of these strategies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the results of studies investigating HAART as prevention in serodiscordant couples and mother-to-child transmission by breastfeeding
  • Discuss the use of acyclovir as a method of biomedical prevention in serodiscordant couples
  • Explain new data on circumcision as a modality of HIV prevention
  • Relate details of modeling exercises that describe the results of HIV testing and prevention interventions at the population level

Topics covered include:

  • Introduction
  • HIV Transmission Risk in Serodiscordant Couples Is Associated With Pregnancy
  • Antiretroviral Therapy Reduces HIV Transmission in Serodiscordant Couples
  • Maternal and Infant Treatment Reduces HIV Transmission During Breastfeeding
  • DREAM Cohort: Increased Duration of Maternal HAART Improves Pregnancy Outcomes and Reduces Mother-to-Child Transmission
  • Acyclovir in HIV/HSV-2–Coinfected Individuals Does Not Reduce HIV Transmission to Uninfected Partners
  • Acyclovir Slows HIV Disease Progression in HIV/HSV-2–Coinfected Individuals
  • Circumcision and Risk of HIV Transmission to Female Uninfected Partners
  • Modeling the Effects of HIV Testing and Prevention Interventions at the Population Level
 

Faculty

  • Sharon L. Hillier
    PhD
    Julio Montaner
    MD, FRCPC, FCCP
    Thomas Quinn
    MD, MSc

Credit Information

  • Release Date:
    September 29, 2009
  • Expiration Date:
    September 28, 2010
  • Physicians:
    maximum of 0.5 AMA PRA Category 1 Credits
  • Registered Nurses:
    0.5 Nursing contact hours
  • Pharmacists:
    0.5 contact hours (0.05 CEUs)
Jointly sponsored by USF Health and Clinical Care Options, LLC.
 
 
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
  • The Shifting Sands of HIV Risk in the US Today: Falling in Women, Rising in Young MSM

    W. David Hardy MD - 2/28/2013    1 comment / Last Comment: 3/15/2013
    The trends I’ve seen in my own practice are consistent with recent data from the CDC on the evolving impact of HIV in the US population.
  • What to Make of the “Functional Cure” of HIV in an Infant

    W. David Hardy MD - 3/28/2013    6 comments / Last Comment: 4/30/2013
    Does this report from CROI have implications for how we manage HIV-exposed infants?
  • PrEP at CROI 2013: How Does This Influence Our Practice?

    Eric S. Daar MD - 3/21/2013    1 comment / Last Comment: 4/23/2013
    Although PrEP can be effective in preventing HIV acquisition, the latest data from CROI further underscore the critical importance of adherence in determining efficacy.
  • Postexposure Prophylaxis: Dealing With Old Guidelines

    Eric S. Daar MD - 2/22/2013    8 comments / Last Comment: 3/28/2013
    While data continues to evolve in HIV research, how do you deal with guidelines that have not yet been updated?
  • Applying OPTIONS: When Can Our Treatment-Experienced Patients Discontinue NRTIs?

    Andrew R. Zolopa MD - 5/8/2013    
    The OPTIONS trial suggested that some treatment-experienced patients may not need NRTIs, but how do you translate this to clinical practice?